Top Ten most popular articles on Pharmafile.com this week
pharmafile | December 9, 2016 | News story | Medical Communications |Â Â top tenÂ
Christmas is drawing ever closer, but that doesn’t mean the industry is slowing down. This week, features from the latest issue of Pharmafocus have had major traction with our readers, with our Biosimilars and Generics feature breaking the top ten for the second week.
There has been a wealth of very promising R&D developments this week which paint an illuminating path forward for future developments, but stories of bribery and fraud have also proven big news.
10. Cannabis-based treatment scores Phase 3 successes for GW Pharma
UK-based GW Pharmaceuticals has unveiled new efficacy data for cannabidiol drug Epidiolex in the treatment of Dravet syndrome and Lennox-Gastaut syndrome (LGS).
9. AZ lung cancer drug cuts disease progression by 70%
New Tagrisso data proves promising for the treatment of epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).
8. Scientists create ‘map of drugs’ to aid further development
Researchers at The Institute of Cancer Research have used drugs licensed through the FDA to create a map of all 1,578 drugs and their mechanism of action. The study revealed that only 667 of the estimated 20,000 human proteins have had drugs developed to act upon them.
7. Looking back at the biggest deal of 2016: Bayer-Monsanto
The industry followed Bayer’s attempts to acquire US agricultural firm Monsanto with fevered anticipation; the takeover eventually closed in September for $66 billion, debt included.
6. Biosimilars and Generics: A no-brainer for treatment?
The industry is poised on the potential widespread adoption of many revolutionary technologies; foremost among them are biosimilars and generics, alternatives to traditional treatment which promise to keep costs low and healthy patients high. Matt Fellows investigates the industry’s complicated relationship with these technologies as it stands today.
5. Technology and patient adherence: Putting control of medication directly in patients’ hands
Spend any time looking into patient adherence and some remarkable figures will come your way: huge losses of money, major pressure placed on healthcare systems and, worryingly, a large number of deaths when patients do not take their medication as advised. What is the solution?
4. New Alzheimer’s research edges closer to treatment & prevention
A new study has shed light on the possible prevention and treatment of Alzheimer’s disease thanks to findings centred on aquaporin-4, a membrane protein in the brain.
3. AstraZeneca seals $1 billion deal with Bicycle Therapeutics
Bicycle Therapeutics, Cambridge-based British biotech firm, has announced that it has signed a deal that could potentially be worth over $1 billion with AstraZeneca.
2. Pfizer slapped with record £84.2 million fine for 2,600% price increase
Pfizer has been hit with a record fine by The Competition and Markets Authority for the increase in the price of phenytoin sodium capsules, a drug designed to help control symptoms of epilepsy.
1. Teva embroiled in internal bribery investigation
Israeli pharmaceutical firm Teva has confirmed it is in the process of an ongoing internal investigation into allegations of bribery, after the company’s chief executive was tipped off by an anonymous informant.
Related Content
Top Ten most popular articles on Pharmafile.com this week
As the year winds to a close, excitement is rising around the efficacy and availability …
Top Ten most popular articles on Pharmafile.com this week
The top ten news stories this week focus on herd immunity, as the Director of …
Pharmafile.com’s weekly COVID-19 news round-up
The coronavirus news this week focuses on the development of treatments to alleviate symptoms of …
